Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Sanofi and GlaxoSmithKline Delay COVID-19 Vaccine Program Due to Poor Immune Response in Older Adults

By Cory Renauer - Dec 11, 2020 at 11:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The vaccine giants will be rethinking the formulation of their coronavirus candidate before a new phase 2 study.

Two of the world's leading vaccine manufacturers have run into a big problem with their joint coronavirus vaccine program. Lackluster immune responses from some of the first patients injected with a candidate developed by Sanofi ( SNY 0.61% ) and GlaxoSmithKline ( GSK 0.92% ) led the partners to announce on Friday morning that they were delaying the phase 3 trial that they'd planned to start this month.

Interim results from the companies' phase 1/2 clinical trial showed the original vaccine formulation generated sufficient immune responses in volunteers aged 18 to 49. Unfortunately, the immune responses it produced in older adults were lower than levels seen among patients who have successfully recovered from COVID-19.

Vaccine administration.

Image source: Getty Images.

The partners aren't abandoning their recombinant protein-based coronavirus vaccine candidate, but the tests of it at its current concentration won't go much further. Instead, Sanofi and GlaxoSmithKline plan to begin a phase 2 clinical trial testing an improved formulation of their COVID-19 vaccine candidate in February.

That study will include a group randomized to receive an authorized vaccine for comparison. This will most likely be a messenger-RNA (mRNA) based vaccine candidate from Moderna ( MRNA 2.67% ), or Pfizer ( PFE -0.20% ), and BioNTech ( BNTX 3.62% ). BNT162b2 from Pfizer and BioNTech is likely to receive emergency use authorization from the FDA on Friday afternoon following the positive outcome of Thursday's independent advisory committee meeting. Moderna's candidate, mRNA-1273 will be the subject of a similar meeting on Dec. 17.

The key component of the vaccine candidate developed by Sanofi is a protein that resembles a portion of the SARS-CoV-2 virus responsible for COVID-19. It's delivered in combination with an adjuvant made by  GlaxoSmithKline to enhance the immune system's response to the antigens. This old-fashioned method of training the immune system has worked for generations, but it's beginning to look like the mRNA-based approach has a strong efficacy advantage. We'll know more when a head-to-head trial reads out next year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$47.85 (0.61%) $0.29
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.38 (-0.20%) $0.10
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$42.15 (0.92%) $0.39
Moderna, Inc. Stock Quote
Moderna, Inc.
$272.41 (2.67%) $7.08
BioNTech SE Stock Quote
BioNTech SE
$289.98 (3.62%) $10.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.